Congresswoman Fischbach Urged to Boost Alzheimer’s Research Funding

Congresswoman Michelle Fischbach faces pressure from constituents to advocate for increased funding for Alzheimer’s research. A recent recommendation from the House Appropriations Committee proposed only a $15 million increase in funding for the National Institutes of Health (NIH) for Fiscal Year 2026. This amount falls significantly short of the $113 million increase that NIH scientists have indicated is necessary to maintain progress in Alzheimer’s research.

In contrast, the Senate Committee has proposed a more substantial increase of $100 million, reflecting a stronger commitment to addressing the challenges posed by this debilitating disease. Alzheimer’s not only impacts families emotionally but also imposes significant financial burdens on the healthcare system, particularly on Medicare.

As a member of the House Ways and Means Committee, Congresswoman Fischbach is acutely aware of the pressures that Alzheimer’s disease places on federal spending and healthcare resources. The disease is one of the most costly for Medicare to manage, highlighting the urgent need for proactive investment in research.

A letter from a concerned constituent articulated this sentiment, emphasizing that investing in Alzheimer’s research is both a fiscal and moral obligation. The letter pointed out that slowing or preventing the disease could save Medicare billions in the long term. The past decade has seen significant advancements in understanding Alzheimer’s, but continued underfunding could hinder future progress.

The constituent urged Congresswoman Fischbach to reconsider the House’s funding stance and to support stronger federal investment in Alzheimer’s research. With the stakes so high for families, caregivers, and future generations, advocates argue that timely action is essential.

Strengthening funding for Alzheimer’s research could play a crucial role in alleviating the emotional and financial burdens faced by countless families. As discussions proceed, the call for enhanced federal support remains a pivotal point of focus for advocates and stakeholders in the healthcare community.